Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020 BRIDGEWATER, N.J., June 8, 2020 -- (Healthcare Sales & Marketing Network) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceu... Biopharmaceuticals, FDA Insmed, brensocatib, bronchiectasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news